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Abstract: Glucoregulatory diseases, such as type 2 diabetes are currently a key public health
priority. Public health messages have started to include the addition of water in their dietary
guidelines. Such guidelines however are not based on causal evidence pertaining to the health
effects of increased water intake, but rather more heavily based upon non-causal or mechanistic
data. One line of thinking linking fluid intake and health is that hypohydration induces elevated
blood concentrations of arginine vasopressin (AVP). Research in the 1970s and 1980s implicated
AVP in glucoregulation, supported by observational evidence. This important area of research
subsequently appeared to stop until the 21st century during which interest in hypertonic saline
infusion studies, animal AVP receptor knockout models, dietary and genetic associations, and
human interventions manipulating hydration status have resurged. This narrative review briefly
describes and critically evaluates the usefulness of the current AVP-glucoregulatory research. We offer
suggestions on how to test the independent glucoregulatory effects of body water changes compared
to elevated circulating AVP concentrations, such as investigating hydration manipulations using
3,4-Methylenedioxymethamphetamine. Whilst much research is still needed before making firm
conclusions, the current evidence suggests that although AVP may be partially implicated in
glucoregulation, more ecologically valid models using human participants suggests this effect might
be independent of the hydration status. The key implication of this hypothesis if confirmed in future
research is that manipulating the hydration status to reduce circulating AVP concentrations may not
be an effective method to improve glucoregulatory health.
Keywords: vasopressin; copeptin; hydration; health; metabolism; glycaemia; type 2 diabetes; diabetes
insipidus; syndrome of inappropriate anti-diuretic secretion; MDMA
1. Introduction
Historically, research in hydration focused on large deviations in hydration status. Specifically, the
ill-effects of severe hypohydration in soldiers under extreme conditions were investigated, resulting
in guidelines for optimal sports performance [1]. Following this, public health guidelines started to
incorporate hydration recommendations; a more detailed description of this shift has been reviewed
previously [1]. Briefly, such recommendations may have oversimplified the complex relationship
between fluid intake and health. One of the most prominent examples is the Institute of Medicine
guidelines which noted that serum osmolality stays within a well-defined range across a multitude
of fluid intakes; subsequent guidelines were therefore based on median intakes of self-reported
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fluid ingestion (‘adequate intake’) [2]. Thus, to date, fluid intake guidelines have not been based on
evidence pertaining to improved health, such as lower risk of glucoregulatory diseases (e.g., type 2
diabetes [T2D]).
Understanding the true causal role of hydration status in health and disease is important in order
that guidelines are based on the best possible evidence. Increasing fluid intake (particularly from
water) as a means to manipulate hydration status (and therefore potentially health) represents a low
cost and easy to understand intervention. Further, the addition of water to the diet does not remove
hedonically rewarding foods or beverages, the removal of which may contribute to poor adherence
when implementing a dietary intervention, though more research is certainly warranted to understand
adherence to recommendations surrounding increasing fluid intake.
One key mechanism linking hydration status to glucoregulatory health is arginine vasopressin
(AVP) which is a hormone implicated in body water regulation. This hormone is typically known for
its impacts on blood pressure regulation, whereby hypohydration (as detected by a 1–2% increase in
serum osmolality) is met by an increase in circulating AVP [3]. The result of this is V2 receptor binding
in the collecting ducts of the kidney, signalling an increase in aquaporin expression and redistribution
to the luminal membrane [4]. This increases water reabsorption, attenuating a reduction in blood
volume when water intake is low [5]. However, it is important to acknowledge that many factors
can alter circulating AVP concentrations, including genetics [6], ambient temperature [7], circadian
rhythms [8], pharmaceuticals [9], recent fluid intake [10], and stress [11]. Thus, the pathway from low
fluid intake to high circulating AVP to poor glucoregulatory health is difficult to examine as the high
AVP may be due to other extraneous variables.
Nonetheless, high plasma concentrations of AVP have been associated with poorer cardiometabolic
and glucoregulatory health [12,13]. Water intake almost immediately reduces plasma copeptin
concentrations (a surrogate marker of AVP [14]) for >4 h. This has led some to hypothesise that
interventions to reduce copeptin via increasing fluid intake may facilitate positive health outcomes
(e.g., [1,10]). This line of thinking may, however, oversimplify the relationship between hydration, AVP,
and health. The aim of this narrative review is to briefly discuss early and current human research in
hydration, AVP, and glucoregulatory health and provide a critical perspective as to how to advance the
field, focusing on uncoupling the effects of hydration status and AVP.
2. History
A summary of the studies discussed herein can be found in Table 1. Much research investigating
the role of AVP in water balance was conducted in the 1970s (e.g., [15,16]) subsequently resulting
in data suggesting AVP may be linked to glucoregulation. In 1979, Zerbe et al. [17] found elevated
plasma AVP concentrations in patients with uncontrolled diabetes mellitus (i.e., hyperglycaemia).
This seemed counterintuitive as hyperglycaemia is typically accompanied by polyuria, which acts to
help maintain euglycaemia. Rather, these patients had severe hypovolemia sufficient enough to induce
AVP secretion. It therefore appeared that hyperglycaemia caused polyuria, resulting in hypovolemia [17].
Consequently, plasma AVP concentrations increased to counteract the loss in blood volume, which
may have been potentiated by the osmotic effect of high blood glucose concentrations [17]. When
treated with insulin (and hydrated), plasma AVP concentration reduced by up to five-fold, along with
concomitant reductions in plasma osmolality [17]. Such findings were key in introducing the idea that
AVP may have a role in glucoregulation.
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Table 1. Literature pertaining to hydration and glucoregulation.
Author, Year Study Design Participants Method/Assessment ofHYPO
Level of HYPO
Achieved
Glucoregulatory
Assessment Findings
OBSERVATIONAL STUDIES
Zerbe et al.,
1979 [17] Cross-sectional
n = 15 men, 13
women with
uncontrolled diabetes
AVP concentrations N/A Disease status ↑ AVP associated with poorgluco-regulation
Enhorning et al.,
2010 [12]
Cross-sectional and
longitudinal
n = 1418 healthy, 364
IFG, 205 T2D men,
2284 healthy, 311 IFG,
160 T2D women
Copeptin concentrations N/A T2D risk
Cross-sectional: ↑ copeptin associated
with ↑ T2D prevalence and IR
Longitudinal: ↑ copeptin associated with
↑ T2D (healthy at baseline OR Q1 vs. Q4
2.64; IFG at baseline OR Q1 vs. Q4 3.48)
Roussel et al.,
2011 [18] Longitudinal
n = 1707 healthy men,
1908 healthy women Plain water intake N/A
Risk of new-onset
hyperglycaemia
↑Water intake associated with ↓ risk of
hyperglycaemia (<0.5 vs. <1.0 and >1.0
L/d OR 0.68–0.79)
Pan et al.,
2012 [19] Longitudinal
n = 82,902 healthy
women Plain water intake N/A T2D risk
× <1 vs. categories up to ≥6 cups/d RR
0.93–1.09
Carroll et al.,
2015 [20] Cross-sectional
n = 60 healthy men,
78 healthy women Plain water intake N/A T2D risk score
↑ 1 cup water/d associated with 0.72 ↓
T2D risk score
Carroll et al.,
2016 [21] Cross-sectional
n = 456 healthy men,
579 health women Plain water intake N/A HbA1c
Men: ↑ 1 cup water/d associated with ↓
0.04% HbA1c
Women: ↑ 1 cup/d associated with ×
HbA1c
Nutrients 2019, 11, 1201 4 of 19
Table 1. Cont.
Author, Year Study Design Participants Method/Assessment ofHYPO
Level of HYPO
Achieved
Glucoregulatory
Assessment Findings
INFUSION STUDIES
Spruce et al.,
1985 [22]
Randomised
crossover trial n = 6 healthy men
IV low then high dose AVP
vs. (isotonic?) IV saline
↑ AVP by ≥15
pmol·L−1
Fasted glucose
kinetics
↑ Arterialised venous blood glucose
concentration (low dose AVP ∆ ~0.3,
high dose ∆ ~0.8 mmol·L−1)
× insulin concentration
↑ glucagon concentration (∆ ~41 pg·L−1)
Keller et al.,
2003 [23]
Randomised
crossover trial n = 10 healthy men
HypoOsm: IV 4 µg
desmopressin + 200 mL/h
water→ IV 4 µg
desmopressin + IV mL/h
0.4% saline; vs. HyperOsm:
IV 1 mL/kg/h 2% saline→ IV
200 mL/h 5%; vs. IsoOsm: ad
libitum water ingestion
HypoOsm: ↓ Posm ~
21 mOsm/kg; ↑ body
mass (~1.6 kg); ↑
urine output (~1.6 L)
HyperOsm: ↑ Posm ~
13 mOsm/kg; × body
mass or urine output
IsoOsm: × Posm, body
mass
Fasting glucose
concentrations and
hyperinsulinaemic-
euglycaemic
clamping
↑Glucose concentration after HyperOsm
(5.1 mmol·L−1) vs. HypoOsm (4.7
mmol·L−1) vs. IsoOsm (4.9 mmol·L−1)
↓ Insulin concentration HypoOsm vs.
IsoOsm and HyperOsm
↑ Endogenous glucose appearance
during HyperOsm vs. IsoOsm and
HypoOsm
Jansen et al.,
2018 [abstract
only] [24]
Randomised
crossover trial n = 30 healthy men
HyperOsm: IV 3.0% saline vs.
IsoOsm: IV 0.9% saline
HyperOsm: ↑ Posm ~
18 mOsm/kg
IsoOsm: ↑ Posm ~ 3
mOsm/kg
OGTT
gluco-regulatory
profile
↑ Glucose concentration at 60 (157 vs.
145 mg·dL−1) and 90 (139 vs. 128
mg·dL−1) min HyperOsm vs. IsoOsm
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Table 1. Cont.
Author, Year Study Design Participants Method/Assessment ofHYPO
Level of HYPO
Achieved
Glucoregulatory
Assessment Findings
WATER INTAKE MANIPULATION STUDIES
Burge et al.,
2001 [25]
Controlled
before-and-after
study
n = 10 men, 5 women
with T1D during
insulin withdrawal
Control (euhydrated) phase
followed by fluid restriction
(750 mL/d) + oral 5 mg
metolazone + IV 40–120 mg
furosemide
↓ Body mass (4.1%); ↓
body water% (~3%)
Fasted insulin
withdrawn
gluco-regulatory
profile (5 h)
↑ Glucose (6.00 vs. 5.88 mmol·L−1),
glucagon (66 vs. 58 ng·L−1), cortisol (497
vs. 384 nmol·L−1) concentrations HYPO
vs. control phase
× Insulin concentration
↓ Glucosuria (13.9 vs. 27.6 g) HYPO vs.
control phase
Carroll et al.,
2016 [26]
Pilot randomised
crossover trial
n = 4 healthy men, 1
healthy woman
HYPO: 45 min sauna + fluid
restriction (≤200 mL water
between sauna and testing)
Control (euhydration): 45
min sauna + ≥ 150% sweat
losses in water between
sauna and testing
↓ Body mass (~1.3%),
↑ urine osmolality (↑
~463 mOsm/kg vs.
control)
Fasted and OGTT
glucose and lactate
concentrations
↑ Glucose concentrations at 45 (5.88 vs.
4.74 mmol·L−1) and 60 (4.87 vs. 4.09
mmol·L−1) HYPO vs. control
↑ Glucose iAUC (72.9 vs. 66.6 mmol ×
120 min·L−1) HYPO vs. control
× Lactate concentration
Johnson et al.,
2017 [27]
Randomised
crossover trial
n = 9 men with T2D
during medication
withdrawal
HYPO: 24–72 h pre-trial, 1
L/d + medication withdrawal
→ 24 h pre-trial, 0.5 L water +
medication withdrawal
Control (euhydration): 72 h
pre-trial 3 L/d water +
medication withdrawal
↓ Body mass (1.5%), ↑
urine specific gravity
(~0.018), urine
osmolality (~482
mOsm/kg), Posm (~10
mOsm/kg), serum
sodium (~3 mEq/L)
HYPO vs. control
Fasted and OGTT
gluco-regulatory
profile
× Fasted glucose, insulin, cortisol,
plasma renin activity, aldosterone
concentrations
↑ Postprandial glucose concentration
HYPO vs. control (AUC 1822 vs. 1689
mmol·L−1·min−1)
× Postprandial insulin, plasma renin
activity, or aldosterone concentrations
↓ Postprandial cortisol concentration
control vs. HYPO (interaction p = 0.017,
but no differences between time points)
Enhorning et
al., 2019 [10]
Randomised
crossover trial
n = 9 healthy men, 28
healthy women
(i) Acute 1 L (vs. 10 mL)
water intake and copeptin
(ii) 1 week 3 L/d added water
intake and copeptin vs.
control (habitual intake)
N/A
Fasted and OGTT
gluco-regulatory
profile
Acute: × glucose or insulin
concentrations during OGTT but ↓
glucagon concentration
1 week intervention: × fasted glucose,
insulin, glucagon concentrations
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Table 1. Cont.
Author, Year Study Design Participants Method/Assessment ofHYPO
Level of HYPO
Achieved
Glucoregulatory
Assessment Findings
WATER INTAKE MANIPULATION STUDIES
Carroll et al.,
2019 [11]
Randomised
crossover trial
n = 8 healthy men, 8
healthy women
HYPO: 1 h heat tent + 3
mL/kg body mass/~34 h
water
Control (euhydration): 1 h
heat tent + 150% sweat losses
+ 40 mL/kg lean body mass in
water
↓ Body mass (1.9%),
CSMA (365 mm2),
muscle water (~11.1
g/kg vs. control), ↑
urine specific gravity
(~0.010), urine
osmolality (~442
mOsm/kg), serum
osmolality (9
mOsm/kg), copeptin
(14.32 pmol·L−1)
× In above after
control condition
Fasted and OGTT
gluco-regulatory
profile
× Fasted or postprandial glucose,
insulin, ACTH, or cortisol
concentrations HYPO vs. control
Abbreviations and symbols: ∆, change; ×, no change/no difference; ~, approximately; ↓, decreased; ↑, increased;→, followed by; ACTH, adrenocorticotropic hormone; AUC, area under
curve; AVP, arginine vasopressin; CSMA, cross-sectional muscle area; d, day; HbA1c, glycated haemoglobin; HYPO, hypohydration; HyperOsm, hyperosmolality trial arm; HypoOsm,
hypoosmolality trial arm; iAUC, incremental area under the curve; IFG, impaired fasting glucose; IR, insulin resistance; IsoOsm, isoosmolality trial arm; IV, intravenous infusion; OGTT,
oral glucose tolerance test; OR, odds ratio; Posm, plasma osmolality; Q, quartile; RR, relative risk; T1D, type 1 diabetes; T2D, type 2 diabetes; vs., versus.
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Following this, in 1985, Spruce et al. [22] advanced this research, along with theory from
research in rodents and dogs (e.g., [28,29]), by infusing AVP into healthy adults and measuring
glucoregulation (including glucose kinetics using labelled glucose). Plasma concentrations of
AVP reached 22.3 ± 5.4 pmol·L−1 during a 30 min low dose infusion (25 pmol·min−1), and
112.3 ± 18.4 pmol·L−1 during a subsequent 60 min high dose infusion (75 pmol·min−1), without altering
plasma osmolality. Arterialised-venous blood glucose concentrations increased from 4.9± 0.1 mmol·L−1
to 5.2 ± 0.2 mmol·L−1 after the low dose infusion and to 5.7 ± 0.2 mmol·L−1 after the high dose.
Such changes were not found after saline infusion (though no details were given regarding the saline
so it is assumed that this was isotonic). No effects from any treatment were found for plasma insulin
concentrations, though plasma glucagon concentrations were ~41 pg·L−1 higher during the low dose
AVP infusion, which remained throughout the high dose infusion.
Such studies offered insights into potential mechanisms by which AVP might be implicated
in glucoregulatory health. Firstly, as can be seen from the work of Zerbe et al. [17], there is
a complex interplay between hyperglycaemia and AVP, potentially mediated by hypovolemia
induced by glucosuria. Although the study was unable to determine the temporal direction of the
hyperglycaemia-AVP relationship, considering the elevated AVP was accounted for by hypovolemia, it
is likely that the hyperglycaemia drove higher AVP, rather than vice versa (Figure 1). The AVP-induced
hyperglycaemia may have also created an osmotic stimulus further stimulating AVP secretion (Figure 1).
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Figure 1. The relationship between diabetes and increased arginine vasopressin, as per the findings of
Zerbe et al. (1979) [17]. Dotted lines represent a feedback loop, which aims to maintain homeostasis.
Dashed line represents a theoretical pathway whereby hyperglycaemia induces an osmotic stimulus for
greater AVP secretion.
Secondly, Spruce et al. [22] demonstrated an increase in glucose production but not disposal at
supraphysiological circulating AVP concentrations; this was likely driven by glycogenolysis, rather than
gluconeogenesis, as there were no changes in gluconeogenic precursors such as lactate. The increase
in glycaemia was therefore likely due to the greater plasma glucagon concentrations during AVP
infusion. The divergence in mechanistic findings of these two studies provides a strong rationale to
separate patients with diseases from healthy participants when making comparisons between theories
and studies.
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Beyond the direct role of AVP on glucoregulation, theoretical implications have also been
hypothesised involving the hypothalamic-pituitary-adrenal (HPA) axis, which were highlighted in the
1980s. The HPA axis is implicated in the stress response which can increase hepatic glucose output.
Upon experiencing stress, AVP and corticotropin-releasing factor (CRF) are synthesised and secreted by
the hypothalamus. These hormones regulate adrenocorticotropic hormone (ACTH) secretion from the
pituitary gland, resulting in cortisol secretion from the adrenal cortex. In the 1980s, there was sufficient
evidence, primarily from animal models, regarding the role of AVP in this response [30]. Specifically,
during physical stress, CRF (a precursor to ACTH) is produced. In vivo, AVP can potentiate the
effect of CRF on ACTH production. As AVP is elevated during physical stress, there remains a clear
pathway between AVP and the stress response, via CRF, ACTH, and ultimately cortisol secretion [30].
Accordingly, it may be that increasing water intake to reduce AVP could mitigate excessive cortisol
secretion, thus reducing hepatic glucose output (Figure 2).
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Figure 2. Theoretical relationship between hydration status, arginine vasopressin, and the
hypothalamic-pituitary-adrenal axis. Dashed lines represent a mediating relationship (i.e., hydration
status directly influences arginine vasopressin, and hydration status may influence stress); dotted
lines represent a moderating relationship (i.e., arginine vasopressin determines the propensity of
corticotropin releasing factor to be cleaved into adrenocorticotropic hormone).
3. Current Research
As discussed in the previous section, the studies conducted in the 1970s and 1980s provided
fascinating insights into the role of hydration and AVP in glucoregulatory health. Yet, despite the
broad ranging implications of the work, interest in AVP waned until the 2000s. Recently, research has
expanded the early work and helped provide some critical perspective.
Water intake can be used as a crude proxy for hydration status. Few studies have investigated the
relationship between water intake and markers of glucoregulatory health. In a French coh rt of men
and women, higher water int ke (assessed via self-reported categories of litres of plain water per day)
was associated with lower risk f hyperglycaemia [18]. This relationship wa replicated in small UK
sample of men and women [20] but ot in a sample of US f male nurses [19] (both of which assessed
water intake using a food frequency questionnaire). Followi g these studies, a r presentative UK
sam le also found an inverse relationship between plai water intake (from four-day unweighed diet
diaries) and glucoregulatory health, though upon further analysis, this association was only found in
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men [21]. This latest study may explain the null relationship found in US nurses [19] due to the sample
being exclusively women, compared to the other studies which used mixed sex samples. Regarding
AVP, this could make sense due to fluctuations in the osmolality set-point for AVP secretion during the
menstrual cycle [31], which may cloud any associations. Alternatively, the unvalidated methods of
fluid intake may not have accurately captured true water intake, explaining the mixed findings.
Further observational evidence has more directly implicated AVP in glucoregulatory health. In a
Swedish sample, higher plasma copeptin (as a surrogate marker of AVP) concentrations were associated
with higher prevalence of T2D and insulin resistance, both cross-sectionally and longitudinally [12].
Advancing these associations are studies investigating variations in AVP receptor genes. Participants
with the variation in the AVP1a receptor gene (specifically, rs1042615 T allele) had a higher prevalence
of T2D in those with a high fat diet or with overweight [32]; similarly AVP1b receptor genes were
tentatively associated with increased T2D risk [33].
Of course, observational evidence has limited causal inference due to well-known problems such
as reverse causality and residual confounding. Particularly in the case of water intake, beyond issues
surrounding misreporting, water intake is part of a cluster of other healthful behaviours such as
higher fibre intake [34], which may confound any associations. In the case of the genetic observations,
these could be chance associations, or AVP receptor genes may be collinear with other genes, which
directly cause disease, thus representing a marker of a different mechanistic process. Nonetheless,
the genetic work shows some agreement with rodent models, which have used knockout models,
improving the confidence in these findings [35]. Alternatively, as the outcome for these studies was
related to glucoregulatory health, there may have been confounding from unmeasured hypovolemia,
in line with the work of Zerbe et al. in those with uncontrolled diabetes mellitus [17]. In other words,
the findings may not be due to changes in hydration status or AVP per se, but rather represent a
response (symptom) to poor glucoregulatory health resulting in glucosuria; AVP then responded to
maintain blood volume in response to excessive urinary water losses.
Following these studies, interest has started to focus on understanding the causal relationship
between hydration status, AVP, and glucoregulation. One study has investigated the acute and
medium-term effects of water ingestion on glucoregulation. In this study, participants consumed one
litre of water, after which their copeptin reduced within 30 min and remained suppressed by ~39%
throughout the full test period of 4 h [10]. Furthermore, after one week of increased water ingestion,
copeptin was reduced by 15% compared to a control week [10]. This study further split participants into
‘responders’ (i.e., copeptin reduced significantly after water ingestion; typically those with habitually
low water intake, high copeptin and elevated urine osmolality) and ‘non-responders’ (i.e., water
ingestion did not meaningfully impact their copeptin; typically those with habitually higher water
intakes and low copeptin) [10]. In ‘responders’, increasing water intake did not result in changes in
plasma glucose or insulin concentrations, but glucagon concentrations did reduce. Such work builds on
that of the AVP infusion study [22], by demonstrating a reverse effect. In other words, AVP infusion [22]
induced higher glucagon concentrations, whereas water intake prescription [10] induced lower
glucagon concentrations by reducing AVP concentrations (via increasing fluid intake). Taken together,
there appears to be a dose-dependent effect of AVP on circulating glucagon concentrations with mixed
findings on whether this impacts glycaemia.
Arginine vasopressin secretion can be induced by small increases in serum osmolality [15].
Accordingly, some studies have investigated the role of hypertonic saline infusion on glucoregulation.
After hypertonic saline and desmopressin infusion plus fluid restriction in healthy adults,
Keller et al. [23] found higher fasted plasma glucose concentrations, coupled with an increase
in endogenous glucose appearance, compared to an iso- and hypo-osmotic trial arm. Similarly,
hypertonic saline infusion before an oral glucose tolerance test (OGTT) resulted in higher postprandial
glucose concentrations 60 and 90 min post-glucose ingestion [24]. It is unclear from these studies
whether the effect seen was directly due to the saline, or indirectly due to hyperosmolality-induced
AVP secretion (or another as yet unknown mechanism).
Nutrients 2019, 11, 1201 10 of 19
In terms of the glucoregulatory impacts of direct manipulations to hydration status, there is
limited current evidence and no replication studies. In 2001, Burge et al. [25] withdrew insulin in male
and female patients (n = 10) with type 1 diabetes (T1D) and hypohydrated them via fluid restriction
(750 mL per 24 h) and both oral and intravenous diuretics, losing on average ~4.1% of their body
mass compared to a euhydrated control arm. Eight h after a set meal, insulin was withdrawn and
biochemistry was measured for five h. Hypohydration resulted in an elevated glycaemic response
compared to the control arm [25]. In a subgroup of participants, hypohydration was found to result
in lower glucosuria compared to the control arm by an amount concordant with the difference in
glycaemia between the two trial arms. Beyond glucosuria, compared to the euhydrated control arm,
hypohydration induced higher plasma glucagon and cortisol concentrations, which may also explain
the higher glycaemia found.
Similarly, Johnson et al. [27] hypohydrated medication-withdrawn men (n = 9) with T2D (~1.6%
body mass loss) via fluid restriction, reporting elevated postprandial serum glucose concentrations with
hypohydration. No differences in plasma insulin were found between trial arms. Mechanistically, there
was no difference in the renin-angiotensin-aldosterone system (RAAS) according to hydration status,
but the authors were unfortunately unable to measure AVP. Nonetheless, plasma cortisol concentrations
were lower 45 min post-glucose ingestion during the euhydration trial arm [27]. However, whilst
there were main effects and interaction effects, no post-hoc differences were found between the trial
arms. Additionally, the time course of change in cortisol concentration does not clearly correspond
to that of the glycaemic response. Thus, it may be that there is an interaction between hydration
status and nutritional status, which mediated a cortisol response, rather than cortisol playing a role in
hydration-induced alterations in glucoregulation. Alternatively, the cortisol trend may be a response
to the medication withdrawal, since it is similar (though with a more rapid onset) to the work in
insulin-withdrawn participants with T1D [25]. Unfortunately, the authors did not measure glucosuria
for comparison with those with T1D [25].
Considering that early work suggested differential mechanisms between those with glucose
dysregulation [17] and those who are healthy [22], we conducted a pilot study in healthy adults. In this
study, we hypohydrated participants using a sauna and fluid restriction protocol and subsequently
conducted an OGTT [26]. As per the research in people with diabetes, we also found a higher glycaemic
response during hypohydration compared to euhydration. The difference in glycaemia emerged after
30 min (slightly earlier than those with T2D [27]). As per the AVP-infusion study by Spruce et al. [22]
we also did not find a difference in lactate in our pilot work [26], though it tended to be higher during
hypohydration 60 min post-glucose ingestion. However, this pilot study lacked rigorous control (e.g.,
verbal compliance only for the 24 h pre-trial standardisation), had a small sample (n = 5), and was
unable to measure mechanisms. The consistency and clarity in the results seemed somewhat incredible,
thus warranting a tightly controlled follow-up study.
Therefore, our follow-up study used much more rigorous pre-trial standardisation (four days of
food, fluid, and physical activity replication) and measured a multitude of mechanisms [11]. In this
study, participants lost ~1.9% body mass during hypohydration, serum osmolality increased by ~9
mOsm·kg−1, and their plasma copeptin concentrations increased from levels typically seen in healthy
adults to levels seen in those with diabetic ketoacidosis [36]. Thus, we are confident that we induced
meaningful changes in both water balance and AVP concentrations.
Despite this, we did not find a difference between trial arms in the arterialised-venous serum
concentrations of glucose or insulin (neither fasted, nor postprandial) [11]. At 45 and 60 min post-glucose
ingestion, there was a small divergence between the trials, similar to our pilot study [26], though these
data were non-significant and non-meaningful (unlike our pilot). Importantly, there were no differences
in fasting or postprandial ACTH or cortisol concentrations, contrary to participants with T1D [25]
and T2D [27]. This may suggest that the interaction between hydration status and cortisol responds
differentially during medication withdrawal in diabetes compared to healthy adults. Additionally,
as our results in healthy adults are divergent to those in diabetes, it seems likely that glucosuria during
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euhydration provides a better explanation of the lower glycaemic responses in participants with
diabetes. This has been suggested to be tested via comparing those with diabetes during medication
withdrawal and prescription [11].
4. Current and Critical Perspectives and Future Research
Current rhetoric surrounding hydration is such that the addition of fluids, primarily water, in the
diet is good for health. This brief narrative review focuses on glucoregulatory health, which has links
to overall metabolic health and disease (such as T2D). It should be noted that the perspectives herein
are solely related to the addition of fluids to improve hydration status (i.e., not substitution of energy
containing beverages) and the impact on glucoregulatory health; other outcomes or contexts may be
altered differentially and therefore may not be applicable to the perspectives presented. For example,
growing evidence suggests higher fluid intake to reduce the concentration of urine may aid in kidney
health [37] or reduce the risk of urinary tract infection recurrence [38], and that hydration status may
influence endocrine responses to exercise [39].
This section therefore aims to: Critically discuss the differences found between participants who are
healthy and who have diabetes; critically evaluate the role of the HPA axis in hypohydration-mediated
AVP secretion; clarify the purpose of interventions that claim to manipulate hydration status (e.g., reduce
urine concentration versus increase body water); and provide suggestions for future research directions,
including methods to uncouple the effects of manipulating hydration status (i.e., body water) and
circulating AVP concentrations. As it stands, there appears to be limited evidence that hydration status
directly alters glucoregulation, particularly in healthy adults. Replicating the current limited research
should therefore be a priority. In those with diabetes, the evidence is clearer (though still only two
studies [25,27]) but is likely an artefact of glucosuria after euhydration since such effects have only been
testing during medication withdrawal. Certainly the glucosuria hypothesis needs to be further examined.
As previously mentioned, direct comparisons between healthy participants and those with
diabetes should be made with caution. Of particular interest is the differential postprandial cortisol
response found when comparing healthy participants [11] to those with diabetes during medication
withdrawal [25,27]. Mechanisms for this interaction are as yet poorly understood but they are unlikely
mediated by AVP or the RAAS. The reason these two mechanisms are unlikely is because: (i) The RAAS
was not different between hypohydration and euhydration in participants with T2D [27]; (ii) AVP
concentrations (measured by copeptin) appear to remain elevated at roughly a constant magnitude
throughout an OGTT [11], though it is unknown if this is the case in diabetes. Thus, this change in
cortisol is more likely to be mediated via other pathways and may be part of a complex interaction
related to medication withdrawal and perhaps nutritional status.
A key underlying theory is that AVP acts along the stress response; thus if an individual is
hypohydrated during stress, higher AVP will result in higher ACTH (due to AVP potentiating the
effects of CRH). Ergo, in theory, maintaining low circulating AVP concentrations would result in
lower CRH cleavage into ACTH, mitigating cortisol-mediated hepatic glucose output (Figure 2).
This pathway was determined primarily from theory and animal models. We, however, found no
evidence that hydration status induced a difference in ACTH or cortisol concentrations, despite
meaningful elevations in copeptin concentrations, even under physical stress (i.e., muscle biopsies) [11].
In healthy adults, a large degree (~5% body mass loss) might be needed to induce an elevation in
fasting circulating cortisol concentrations [39], which is not representative of daily fluctuations in
the water balance. At a more typical level of body mass loss (~2.5%) no differences were found in
cortisol concentrations [39], in accordance with our data [11]. Such differences between 2.5% and
5% hypohydration may help explain why the high dose AVP infusion caused higher plasma glucose
compared to the low dose in previous work (18). Thus, if AVP does potentiate the effects of CRF, this is
unlikely via hydration-mediated AVP changes, at least during every day fluctuations in water balance.
If we therefore examine the totality of evidence critically, one of the conclusions that could be
made is that AVP is maybe only partially implicated in glucoregulation, however this is perhaps
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independent of hydration status. In other words, our hypothesis is that the physiological effects of
hypohydration-induced AVP secretion counter-regulate AVP-induced hyperglycaemia, or the effects of
increased AVP from other (non-hydration related) causes interact to cause hyperglycaemia, similar to
the potential interaction between nutritional status and cortisol secretion found in those with T2D [27].
Alternatively, it could be that there is a residual factor, as yet unknown, that influences both AVP and
glucoregulation that is context-specific, thereby explaining why there appears to be no direct effect of
hypohydration on glucoregulation, whereas there does appear to be an effect of AVP infusion. Thus,
we propose that there are potentially differences in the physiological responses to hydration status
that alter glucoregulation, according to whether the response is exogenous (e.g., infusion of AVP),
or endogenous (e.g., restricting fluid to raise circulating AVP).
Therefore, we hypothesise that manipulating hydration status in order to reduce AVP is likely to
have minimal, if any effect, on glucoregulation, at least in healthy populations. This has somewhat
been demonstrated in the aforementioned one week water intervention (+3 L·day−1 added to habitual
intake) [10]. Responders to the intervention had a reduction in fasting plasma glucagon concentrations,
but not glucose or insulin concentrations, concordant with the increase in glucagon concentrations
found during AVP infusion [22]. Such results add credence to the idea that reducing AVP (measured
by copeptin) fails to alter glucoregulation in otherwise healthy individuals, despite increasing
glucagon. This perhaps suggests that another counter-regulatory process is occurring to mitigate the
hyperglycaemic effects of glucagon. Considering studies investigating those with T1D [25], healthy
adults prescribed high water intake [10], and AVP infusion [22], researchers should ensure that
glucagon is measured so the effects on primary glucoregulatory hormones can be captured. It is unclear
mechanistically why glucagon increased in these studies but did not always result in higher plasma
glucose concentrations.
Our hypothesis is specific to endogenous AVP production mediated by non-compartment-specific
hypohydration. It has been demonstrated that AVP infusion increases glucose concentrations without
increasing serum osmolality (i.e., without necessarily altering hydration status per se) [8]. Although
there has been no replication work to confirm these findings, some studies have shown an increase in
glycaemia when infusing hypertonic (2–5%) saline (which will likely raise AVP concentrations) (12 h
hypertonic saline at 1 mL·kg·h−1 followed by 3 h at 200 mL·kg·h−1 [23]; and 2 h hypertonic saline
infusion at 0.1 mL·kg·h−1 [24]). In the AVP infusion study by Spruce et al. [22] no effect on blood glucose
concentrations was observed after saline infusion (which did not alter AVP concentrations), though
details regarding the properties of the infused saline were not given; thus as no effect of infusion was
found, it is likely they used isotonic saline, concordant with the control groups in the studies infusing
hypertonic saline [23,24]. It is unclear if AVP was altered in these other saline infusion studies [23,24].
Discordance between the AVP infusion [22] and hypohydration-induced AVP elevations [11] may
also be explained by nutritional status, i.e., fasted AVP infusion resulted in greater hepatic glucose
output (but no change in glucose disposal), whereas in a postprandial state, glucose disposal is more
pertinent. This perhaps suggests that AVP acts specifically to increase hepatic glucose metabolism,
which may be more directly influenced by infusion studies that create intracellular dehydration.
Such intracellular dehydration, particularly in hepatocytes, has been shown to increase glucagon
secretion and is thus implicated in glucoregulation [40,41] and could help explain the aforementioned
higher glucagon concentrations.
Taken together, these findings may point towards AVP being the main factor in glucoregulation,
rather than increased serum osmolality having independent effects (Figure 3). Alternatively or
additionally, such studies suggest that both (a) exogenous AVP, and (b) compartmental water
distribution changes can result in increased glycaemia. Whilst these are important mechanistic
insights, they are not necessarily valid for every day fluctuations in water balance in humans. Further,
they may represent a physiological condition present in some people due to other factors such as
genetic variations (i.e., not hypohydration).
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A counter argument to our hypothesis may be differences related to genetic influences [32,33].
Although these studies highlight genetic variation relating to AVP (and therefore by inference water
balance physiology) are correlated to poorer glucoregulatory and metabolic health outcomes, they lack
causality. Specifically, such genetic variations may be collinear with other genetic variations that are
detrimental to health. If, for the sake of argument, we assume the association is causal, such findings
may mean that genetic variation in water balance physiology can cause increased risk of cardiometabolic
disease. However, this does not automatically mean that altering water balance behaviours (i.e.,
increasing fluid intake) will reduce this genetically determined disease risk. This of course should be
further investigated as perhaps targeting people with certain variants could increase the likelihood that
a water intervention might be efficacious (and in the case of the previously discussed water-prescription
study by Enhorning et al. [10], may explain some variation in the responders and non-responders).
Further considerations should also be taken into account in future research. Firstly, the
epidemiology investigating water intake and glucoregulatory health is at least suggestive of sex
differences. Considering that much physiology research is based on men (e.g., [27]), or when women
are included they are in their (estimated) follicular phase, post-menopausal, or taking hormonal
contraceptives (e.g., [11]), studies investigating water balance and health outcomes during the luteal
phase of the menstrual cycle would be of mechanistic interest. The osmolality set point for AVP
secretion changes throughout the menstrual cycle [31] as does carbohydrate and fat oxidation [42] and
understanding how these fluctuations influence health would aid in our mechanistic understanding of
whether and how AVP influences glucoregulatory health.
Secondly, pre-trial control of known confounding factors should be emphasised. Our recent study
included four days of pre-trial diet, activity, and fluid intake standardisation using weighed food
diaries and combined accelerometry and heart rate monitors [11]. Such control to our knowledge has
not been utilised in previous hydration and health related research. To demonstrate why this may be
important, comparatively, our pilot work used 24 h of diet and activity standardisation in the form of
verbal confirmation [26]. The stark differences in the results from these studies may indicate that lack of
pre-trial standardisation at least partially contributed to divergences in glucoregulation during the OGTT.
Thirdly, another explanation as to why there have been conflicting findings, may be the use of
venous versus arterialised-venous blood. In our pilot work, we used venous blood and found a large
difference in the blood glucose response between hydration states [26]. Contrarily, in our follow-up
study, we used arterialised-venous blood [11]. As arterialised-venous blood more closely represents
the glucose concentration that cells are exposed to, whereas venous blood more closely represents the
glucose the cells have not taken up, it is reasonable to suspect that this may (at least in part) explain the
differences in our findings [43]. Whilst this is a possibility that warrants further investigation, it is
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worth noting the use of arterialised-venous blood during AVP infusion [22], which still demonstrated
a difference in glycaemia. This of course may also be due to the use of exogenous AVP infusion versus
endogenous AVP via dehydration.
Further adding doubt to the arterialisation theory is that in our study, after the OGTT, we measured
multiple facets of appetite, including serum glucose and insulin concentrations from (non-arterialised)
venous blood after an ad libitum test meal. During this period of testing, plasma copeptin concentrations
and serum osmolality remained elevated during hypohydration but blood glucose and insulin
concentrations remained remarkably similar to the euhydrated trial arm [44]. Whilst the ad libitumnature
of the test meal confounds any definitive inferences, energy intake was (on average) approximately
equal between the trial arms, and accordingly, there were no differences in serum glucose or insulin
concentrations. If arterialisation was a cause of the disparities between studies, it may have been
apparent during this period of testing.
A final consideration is the measurement of hydration status and how this relates to the conclusions
of studies. There is currently no gold standard measure of hydration, as each method has its strengths
and limitations according to the context. Our recent study, to our knowledge, measured hydration
status more extensively than any other research investigating hydration and health [11], including body
mass, plasma copeptin concentration, urine and serum osmolality, urine specific gravity, peripheral
quantitative computer tomography, muscle biopsies, and fluid intake diaries. Whilst this level of
measurement is unnecessary for all research, future work should consider the appropriateness of the
measures taken, and a clear distinction needs to be made before starting the trial: Is the aim to alter
urine concentration, AVP, or body water?
If the aim of the study is to increase urine volume or decrease urine concentration, then measures
such 24-h urine volume, urine osmolality, or urine specific gravity are suitable. However, these measures
alone do not indicate that hydration status has been altered, though they may be sufficient to infer
(with caution) that AVP has been manipulated. Changes in these outcomes simply demonstrates that
the body has no (or at least less) need to reabsorb extra fluid, or fluid has been consumed in a way that
is conducive to increased/decreased urinary output such as consuming a large bolus of fluid rapidly
(e.g., Shafiee et al. [45]).
Equally, measuring AVP (or a marker of) alone does not necessarily infer that body water
(hydration status) has been altered. Arginine vasopressin is secreted in order to reduce water losses.
Thus at least in the early phase of elevated concentrations, it should be effective at maintaining water
balance within the body. Acutely, measuring body mass can be effectively used to determine whether
body water has been altered, though this implies energy balance, emphasising the importance of
proper pre-measure standardisation of diet and activity. Therefore, it is essential to specify the aim of
the study, use the appropriate (combination of) measures, and most importantly to frame conclusions
within the correct context (i.e., are the inferences based on reducing urine concentration, circulating
AVP, or manipulating body water)?
This raises a wider question regarding how we can improve the measurement of hydration status
and accurately assess the contribution of hydration-mediated changes in AVP on glucoregulatory health.
We propose two potential pathways that could help uncouple the independent effects of alterations in
body water and circulating AVP concentrations: (i) Investigating 3,4-Methylenedioxymethamphetamine
(MDMA), and (ii) investigating those with water balance conditions, namely the syndrome of
inappropriate antidiuretic hormone (another name for AVP) secretion (SIADH) and diabetes insipidus.
3,4-Methylenedioxymethamphetamine is the psychoactive ingredient in the recreational drug
more commonly known as ‘ecstasy’. In terms of hydration, this drug is most fascinating as it
gives the symptoms of hypohydration (reduced urine volume, and increased urine osmolality
[despite greater fluid ingestion], plasma copeptin concentrations, thirst, desire for fluid, dry mouth,
and body temperature), whilst simultaneously causing cell swelling (due to the elevation of AVP
resulting in hyponatraemia and greater water retention, as well as the greater fluid ingestion) [36].
Mixed effects have been found for whether plasma osmolality changes from MDMA administration:
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Two placebo-controlled studies found no effect [46,47], whereas another natural study taking pre-
and post-clubbing measured in self-administering participants found a post-MDMA reduction in
plasma osmolality [48], with similar results in another placebo-controlled trial though this study did
not find an interaction between MDMA and AVP [49]. As studies varied in their levels of control
regarding fluid intake, physical activity, and dosage, the effects of MDMA on plasma osmolality need
to be clarified in order to fully understand the hydration-AVP-health interactions (described below).
For example, if serum osmolality remains unchanged post-MDMA administration, this would provide
clear evidence for the effects of AVP on glucoregulation, independent of other hydration-related factors.
Accordingly, MDMA could (a) help improve our understanding of hydration physiology and
measurement, and (b) provide a useful model to help assess the role of AVP in glucoregulatory
health. With regards to the first point (a), if we were able to find a simple measure of hydration that
accurately describes those under the influence of MDMA as hyperhydrated, despite the overwhelming
symptoms of hypohydration, we may more effectively be able to assess hydration status. Additionally,
such MDMA-induced symptoms have some sex-differences (specifically that copeptin concentration
increase more in women than men [47]), further highlighting the usefulness of an MDMA model in
understanding the mechanisms surrounding water balance. An unintended consequence of pursuing
this line of research may be a reduction in MDMA-related deaths, which are primarily caused by
hyponatraemia or hyperhydration.
Regarding the latter point (b), considering MDMA results in both elevated AVP and
hyperhydration, if AVP was the cause of hyperglycaemia, this should mean MDMA induces
hyperglycaemia. Of course this is very difficult to test for several reasons, such as ethical and
legal restrictions, and confounding factors in natural settings such as the temperature and activity
patterns of users. As such, there is very limited research. In rats, MDMA administration results in
hypoglycaemia [50]. However, in humans administered MDMA in a natural setting, but with no
control of food or fluid intake, six out of 21 participants had a non-significant elevation in blood glucose
concentrations compared to baseline [51].
It is unclear as to whether MDMA increases circulating cortisol concentrations or not. In a club
setting, MDMA increased cortisol [52], whereas in a placebo-controlled setting it did not [46], meaning
it is unclear as to whether euglycaemia was maintained in MDMA administered in a natural setting [51]
despite changes in cortisol secretion. It may be concluded from these studies that MDMA-induced
endogenous AVP secretion is at least not associated with glucose dysregulation. Using an MDMA
model of AVP physiology and glucoregulatory outcomes may be useful in aiding our understanding
of these complex relationships as it enables us to uncouple the mechanistic effects of hydration status
and AVP. Nonetheless, caution should still be taken when making inferences from such results to the
general population as MDMA affects a multitude of metabolic and neuronal pathways, which could
also be implicated in glucoregulation. However, this does not necessarily detract from the mechanistic
understanding that such a model can bring.
Following on from an MDMA model, is investigating effects in those with SIADH. This condition is
characterised by low serum osmolality (which can be accompanied by cell swelling and hyponatraemia),
highly concentrated urine, and elevated AVP [53]; thus in some ways this condition mimics the water
balance effects of MDMA administration [46,48,54] and could also be used as a model to uncouple
the effects of body water compared to AVP in glucoregulatory health. Conversely, neurohypophyseal
diabetes insipidus is the underproduction of AVP resulting in excessive fluid losses [55] (though there
are other forms which can result in elevated AVP, e.g., nephrogenic diabetes insipidus [56]).
We were unable to find data regarding glucoregulatory health in either of these conditions. If the
AVP-induced hyperglycaemia model were correct, we would expect to see a greater prevalence of
markers of glucose intolerance (e.g., impaired fasting glucose, or higher T2D prevalence) in those with
SIADH, and lower prevalence in those with diabetes insipidus. In the absence of clear current data,
the relationship between diabetes insipidus and mellitus was previously of interest in the early 1900s;
although there were some cases of increased glucosuria with diabetes insipidus, there was no evidence
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that diabetes mellitus prevalence was different from the general population [57]. Epidemiological work
could investigate this relationship further in order to discern whether more causal work is warranted.
As with MDMA research, inferences from both SIADH and diabetes insipidus models should be
made cautiously when extrapolating to the general population; for example, in SIADH, inappropriate
secretin secretion is currently the most likely cause of the condition, rather than problems with the
AVP response per se [58]. Further, the study of those with diabetes insipidus may help to uncouple
the effects of glucosuria and glucoregulation found in those with T1D and T2D during medication
withdrawal; this may however, additionally reduce the applicability of this model to the general
population. Nonetheless, such models provide useful mechanistic understandings, which can help
drive future hypotheses.
Future research should also consider longer-term interventions. Whilst this has ethical implications,
there is ample evidence to suggest that some people are chronic low fluid drinkers; understanding
the causal implications of this behaviour is essential for public health. Although the acute evidence
in healthy adults at least suggests that such an intervention will not cause metabolic harm, reducing
some initial ethical concerns, important questions remain to be answered as to whether this lack of
harm extends beyond a matter of days. In other words, does chronically high AVP induced by low
fluid intake eventually fulfill the HPA axis causing elevated cortisol (notwithstanding other potential
mechanisms such as changes in cell volume which may influence glucoregulation [40,41]).
Finally, much of the mechanistic work relating AVP to glucoregulatory health has involved isolating
a single mechanism (AVP in the case of the focus of this review, but also hepatocyte volume and more
recently, adipocyte AVP receptor expression). Such studies are vitally important for understanding the
underlying physiology and generating testable hypotheses. However, the more recent work in humans,
which has encompassed the full range of the physiological effects of hypohydration, demonstrates that
such models are not necessarily applicable to human fluctuations in water balance. Thus in order to
understand the glucoregulatory impacts of AVP, ecologically valid methods should be used in order to
make accurate inferences applicable to human health.
5. Conclusions
Overall, this narrative review provided a brief account of the history of AVP-glucoregulation
related research. Whilst the earlier research gave insight into potential mechanisms backed by
observational studies, tightly controlled studies do not at this time appear to support a causal role for
hypohydration-induced increases in AVP on glucoregulatory health. Although studies in people with
diabetes show euhydration results in lower glycaemia, this is likely due to glucosuria from medication
withdrawal; though more research needs to confirm this. Such findings in their totality suggest
that AVP may be implicated in glucoregulation particularly at supraphysiological concentrations,
but possibly not via every day alterations in non-compartment-specific hydration status, at least in
healthy (young) adults. However, research in this field using ecologically valid methods in both
healthy participants and those with diabetes is in its infancy. Several ideas for further examining
mechanisms and outcomes were also discussed, with an emphasis on replication of current studies.
Author Contributions: Conceptualization, H.A.C.; Writing—original draft preparation, H.A.C.; Writing—review
and editing, H.A.C., L.J.J.; Visualization, H.A.C.; Supervision, L.J.J.; Funding acquisition, H.A.C.
Funding: This research was funded by the Economic and Social Research Council, grant number ES/J50015X/1.
Conflicts of Interest: H.A.C. has accepted conference fees to the Danone Nutricia Hydration for Health conference
in 2016, 2017, 2018, and 2019, and has had research funded by the International Chair for Advanced Studies on
Hydration (formerly the European Hydration Institute) Graduate Research Grant. L.J.J. has previously received
funding for research from PepsiCo Inc. and the European Hydration Institute. Additionally, L.J.J. has received
honoraria for talks given at conferences from PepsiCo Inc. and performed consultancy from Lucozade Ribena
Suntory Ltd. This funding/honoraria/ consultancy has always been paid to L.J.J.’s institution and not to L.J.J.
directly. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data;
in the writing of the manuscript, or in the decision to publish the results.
Nutrients 2019, 11, 1201 17 of 19
References
1. Perrier, E.T. Shifting Focus: From Hydration for Performance to Hydration for Health. Ann. Nutr. Metab.
2017, 70 (Suppl. 1), 4–12. [CrossRef]
2. Institute of Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate; National
Academies Press: Washington, DC, USA, 2004.
3. Robertson, G.L. Abnormalities of thirst regulation. Kidney Int. 1984, 25, 460–469. [CrossRef] [PubMed]
4. Thornton, S.N. Thirst and hydration: Physiology and consequences of dysfunction. Physiol. Behav. 2010, 100,
15–21. [CrossRef] [PubMed]
5. Johnson, A.K. The sensory psychobiology of thirst and salt appetite. Med. Sci. Sports Exerc. 2007, 39,
1388–1400. [CrossRef] [PubMed]
6. National Center for Biotechnology Information. AVP: Arginine Vasopressin [Homo Sapiens (Human)]; National
Center for Biotechnology Information: Bethesda, MD, USA, 2019.
7. Segar, W.E.; Moore, W.W. The regulation of antidiuretic hormone release in man: I. Effects of change in
position and ambient temperature on blood ADH levels. J. Clin. Investig. 1968, 47, 2143–2151. [CrossRef]
[PubMed]
8. George, C.P.; Messerli, F.H.; Genest, J.; Nowaczynski, W.; Boucher, R.; Kuchel Orofo-Oftega, M. Diurnal
variation of plasma vasopressin in man. J. Clin. Endocrinol. Metab. 1975, 41, 332–338. [CrossRef] [PubMed]
9. Vuong, C.; Van Uum, S.H.; O’Dell, L.E.; Lutfy, K.; Friedman, T.C. The effects of opioids and opioid analogs
on animal and human endocrine systems. Endocr. Rev. 2010, 31, 98–132. [CrossRef]
10. Enhorning, S.; Tasevska, I.; Roussel, R.; Bouby, N.; Persson, M.; Burri, P.; Bankir, L.; Melander, O. Effects of
hydration on plasma copeptin, glycemia and gluco-regulatory hormones: A water intervention in humans.
Eur. J. Nutr. 2019, 58, 315–324. [CrossRef] [PubMed]
11. Carroll, H.A.; Templeman, I.; Chen, Y.C.; Edinburgh, R.M.; Burch, E.K.; Jewitt, J.T.; Povey, G.; Robinson, T.D.;
Dooley, W.L.; Jones, R.; et al. Effect of acute hypohydration on glycemic regulation in healthy adults:
A randomized crossover trial. J. Appl. Physiol. (1985) 2019, 126, 422–430. [CrossRef]
12. Enhorning, S.; Wang, T.J.; Nilsson, P.M.; Almgren, P.; Hedblad, B.; Berglund, G.; Struck, J.; Morgenthaler, N.G.;
Bergmann, A.; Lindholm, E.; et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010, 121,
2102–2108. [CrossRef]
13. Enhorning, S.; Struck, J.; Wirfalt, E.; Hedblad, B.; Morgenthaler, N.G.; Melander, O. Plasma copeptin, a
unifying factor behind the metabolic syndrome. J. Clin. Endocrinol. Metab. 2011, 96, E1065–E1072. [CrossRef]
[PubMed]
14. Morgenthaler, N.G.; Struck, J.; Jochberger, S.; Dunser, M.W. Copeptin: Clinical use of a new biomarker.
Trends Endocrinol. Metab. TEM 2008, 19, 43–49. [CrossRef] [PubMed]
15. Robertson, G.L.; Athar, S. The intraction of blood osmolality and blood volume in regulating plasma
vasopressin in man. J. Clin. Endocrinol. Metab. 1976, 42, 613–620. [CrossRef] [PubMed]
16. Robertson, G.L. The Regulation of Vasopressin Function in Health and Disease. In Proceedings of the 1976
Laurentian Hormone Conference; Academic Press: Cambridge, MA, USA, 1977; pp. 333–385. [CrossRef]
17. Zerbe, R.L.; Vinicor, F.; Robertson, G.L. Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes 1979,
28, 503–508. [CrossRef] [PubMed]
18. Roussel, R.; Fezeu, L.; Bouby, N.; Balkau, B.; Lantieri, O.; Alhenc-Gelas, F.; Marre, M.; Bankir, L.; D.E.S.I.R.
Study Group. Low water intake and risk for new-onset hyperglycemia. Diabetes Care 2011, 34, 2551–2554.
[CrossRef] [PubMed]
19. Pan, A.; Malik, V.S.; Schulze, M.B.; Manson, J.E.; Willett, W.C.; Hu, F.B. Plain-water intake and risk of type 2
diabetes in young and middle-aged women. Am. J. Clin. Nutr. 2012, 95, 1454–1460. [CrossRef] [PubMed]
20. Carroll, H.A.; Davis, M.G.; Papadaki, A. Higher plain water intake is associated with lower type 2 diabetes
risk: A cross-sectional study in humans. Nutr. Res. 2015, 35, 865–872. [CrossRef] [PubMed]
21. Carroll, H.A.; Betts, J.A.; Johnson, L. An investigation into the relationship between plain water intake and
glycated Hb (HbA1c): A sex-stratified, cross-sectional analysis of the UK National Diet and Nutrition Survey
(2008–2012). Br. J. Nutr. 2016, 116, 1770–1780. [CrossRef] [PubMed]
22. Spruce, B.A.; McCulloch, A.J.; Burd, J.; Orskov, H.; Heaton, A.; Baylis, P.H.; Alberti, K.G. The effect of
vasopressin infusion on glucose metabolism in man. Clin. Endocrinol. 1985, 22, 463–468. [CrossRef]
Nutrients 2019, 11, 1201 18 of 19
23. Keller, U.; Szinnai, G.; Bilz, S.; Berneis, K. Effects of changes in hydration on protein, glucose and lipid
metabolism in man: Impact on health. Eur. J. Clin. Nutr. 2003, 57 (Suppl. 2), S69–S74. [CrossRef]
24. Jansen, L.T.; Suh, H.G.; Sprong, C.; Adams, J.D.; Butts, C.; Seal, A.; Scott, D.; Melander, O.; Lemetais, G.;
Dolci, A.; et al. Hypertonic saline infusion affects glycemic responses following glucose load in healthy men.
FASEB J. 2018, 32 (Suppl. 1), 597.4.
25. Burge, M.R.; Garcia, N.; Qualls, C.R.; Schade, D.S. Differential effects of fasting and dehydration in the
pathogenesis of diabetic ketoacidosis. Metab. Clin. Exp. 2001, 50, 171–177. [CrossRef] [PubMed]
26. Carroll, H.A.; Johnson, L.; Betts, J.A. Effect of hydration status on glycemic control: A pilot study.
In Proceedings of the American College of Sports Medicine, Boston, MA, USA, 31 May–4 June 2016.
27. Johnson, E.C.; Bardis, C.N.; Jansen, L.T.; Adams, J.D.; Kirkland, T.W.; Kavouras, S.A. Reduced water intake
deteriorates glucose regulation in patients with type 2 diabetes. Nutr. Res. 2017, 43, 25–32. [CrossRef]
[PubMed]
28. Bergen, S.S., Jr.; Sullivan, R.; Hilton, J.G.; Willis, S.W., Jr.; Van Itallie, T.B. Glycogenolytic effect of vasopressin
in the canine liver. Am. J. Physiol. 1960, 199, 136–138. [CrossRef] [PubMed]
29. Ma, G.Y.; Hems, D.A. Inhibition of fatty acid synthesis and stimulation of glycogen breakdown by vasopressin
in the perfused mouse liver. Biochem. J. 1975, 152, 389–392. [CrossRef] [PubMed]
30. Gibbs, D.M. Vasopressin and oxytocin: Hypothalamic modulators of the stress response: A review.
Psychoneuroendocrinology 1986, 11, 131–139. [CrossRef]
31. Stachenfeld, N.S. Sex hormone effects on body fluid regulation. Exerc. Sport Sci. Rev. 2008, 36, 152–159.
[CrossRef]
32. Enhorning, S.; Leosdottir, M.; Wallstrom, P.; Gullberg, B.; Berglund, G.; Wirfalt, E.; Melander, O. Relation
between human vasopressin 1a gene variance, fat intake, and diabetes. Am. J. Clin. Nutr. 2009, 89, 400–406.
[CrossRef]
33. Enhorning, S.; Sjogren, M.; Hedblad, B.; Nilsson, P.M.; Struck, J.; Melander, O. Genetic vasopressin 1b
receptor variance in overweight and diabetes mellitus. Eur. J. Endocrinol. 2016, 174, 69–75. [CrossRef]
34. Kant, A.K.; Graubard, B.I.; Atchison, E.A. Intakes of plain water, moisture in foods and beverages, and total
water in the adult US population–nutritional, meal pattern, and body weight correlates: National Health
and Nutrition Examination Surveys 1999–2006. Am. J. Clin. Nutr. 2009, 90, 655–663. [CrossRef]
35. Tanoue, A. New Topics in Vasopressin Receptors and Approach to Novel Drugs: Effects of Vasopressin
Receptor on Regulations of Hormone Secretion and Metabolisms of Glucose, Fat, and Protein. J. Pharmacol. Sci.
2009, 109, 50–52. [CrossRef] [PubMed]
36. Walsh, C.H.; Baylis, P.H.; Malins, J.M. Plasma arginine vasopressin in diabetic ketoacidosis. Diabetologia 1979,
16, 93–96. [CrossRef] [PubMed]
37. Clark, W.F.; Sontrop, J.M.; Huang, S.H.; Moist, L.; Bouby, N.; Bankir, L. Hydration and Chronic Kidney
Disease Progression: A Critical Review of the Evidence. Am. J. Nephrol. 2016, 43, 281–292. [CrossRef]
[PubMed]
38. Hooton, T.M.; Vecchio, M.; Iroz, A.; Tack, I.; Dornic, Q.; Seksek, I.; Lotan, Y. Effect of Increased Daily Water
Intake in Premenopausal Women with Recurrent Urinary Tract Infections: A Randomized Clinical Trial.
JAMA Intern. Med. 2018, 178, 1509–1515. [CrossRef] [PubMed]
39. Judelson, D.A.; Maresh, C.M.; Yamamoto, L.M.; Farrell, M.J.; Armstrong, L.E.; Kraemer, W.J.; Volek, J.S.;
Spiering, B.A.; Casa, D.J.; Anderson, J.M. Effect of hydration state on resistance exercise-induced endocrine
markers of anabolism, catabolism, and metabolism. J. Appl. Physiol. (1985) 2008, 105, 816–824. [CrossRef]
[PubMed]
40. Haussinger, D.; Lang, F.; Gerok, W. Regulation of cell function by the cellular hydration state. Am. J. Physiol.
1994, 267, E343–355. [CrossRef] [PubMed]
41. Haussinger, D. The role of cellular hydration in the regulation of cell function. Biochem. J. 1996, 313 Pt 3,
697–710. [CrossRef]
42. Bisdee, J.T.; Garlick, P.J.; James, W.P.T. Metabolic changes during the menstrual cycle. Br. J. Nutr. 2007, 61,
641. [CrossRef]
43. Liu, D.; Moberg, E.; Kollind, M.; Lins, P.E.; Adamson, U.; Macdonald, I.A. Arterial, arterialized venous,
venous and capillary blood glucose measurements in normal man during hyperinsulinaemic euglycaemia
and hypoglycaemia. Diabetologia 1992, 35, 287–290. [CrossRef]
Nutrients 2019, 11, 1201 19 of 19
44. Carroll, H.A.; Templeman, I.; Chen, Y.-C.; Edinburgh, R.M.; Burch, E.K.; Jewitt, J.T.; Povey, G.; Robinson, T.D.;
Dooley, W.L.; Rogers, P.J.; et al. The effect of hydration status on glycaemic control and appetite regulation.
Ann. Nutr. Metab. 2018, 72 (Suppl. 2), 42–43. [CrossRef]
45. Shafiee, M.A.; Charest, A.F.; Cheema-Dhadli, S.; Glick, D.N.; Napolova, O.; Roozbeh, J.; Semenova, E.;
Sharman, A.; Halperin, M.L. Defining conditions that lead to the retention of water: The importance of the
arterial sodium concentration. Kidney Int. 2005, 67, 613–621. [CrossRef] [PubMed]
46. Henry, J.A.; Fallon, J.K.; Kicman, A.T.; Hutt, A.J.; Cowan, D.A.; Forsling, M. Low-dose MDMA (“ecstasy”)
induces vasopressin secretion. Lancet 1998, 351, 1784. [CrossRef]
47. Simmler, L.D.; Hysek, C.M.; Liechti, M.E. Sex differences in the effects of MDMA (ecstasy) on plasma copeptin
in healthy subjects. J. Clin. Endocrinol. Metab. 2011, 96, 2844–2850. [CrossRef] [PubMed]
48. Wolff, K.; Tsapakis, E.M.; Winstock, A.R.; Hartley, D.; Holt, D.; Forsling, M.L.; Aitchison, K.J. Vasopressin and
oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J. Psychopharmacol.
2006, 20, 400–410. [CrossRef] [PubMed]
49. Baggott, M.J.; Garrison, K.J.; Coyle, J.R.; Galloway, G.P.; Barnes, A.J.; Huestis, M.A.; Mendelson, J.E. MDMA
Impairs Response to Water Intake in Healthy Volunteers. Adv. Pharmacol. Sci. 2016, 2016, 2175896. [CrossRef]
50. Soto-Montenegro, M.L.; Vaquero, J.J.; Arango, C.; Ricaurte, G.; Garcia-Barreno, P.; Desco, M. Effects of MDMA
on blood glucose levels and brain glucose metabolism. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 916–925.
[CrossRef] [PubMed]
51. Downing, J. The psychological and physiological effects of MDMA on normal volunteers. J. Psychoact. Drugs
1986, 18, 335–340. [CrossRef] [PubMed]
52. Wolff, K.; Tsapakis, E.M.; Pariante, C.M.; Kerwin, R.W.; Forsling, M.L.; Aitchison, K.J. Pharmacogenetic
studies of change in cortisol on ecstasy (MDMA) consumption. J. Psychopharmacol. 2012, 26, 419–428.
[CrossRef] [PubMed]
53. Gross, P. Clinical management of SIADH. Ther. Adv. Endocrinol. Metab. 2012, 3, 61–73. [CrossRef] [PubMed]
54. Hartung, T.K.; Schofield, E.; Short, A.I.; Parr, M.J.A.; Henry, J.A. Hyponatraemic states following
3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) ingestion. QJM-Int. J. Med. 2002, 95, 431–437.
[CrossRef] [PubMed]
55. Robertson, G.L. Diabetes Insipidus. Endocrinol. Metab. Clin. N. Am. 1995, 24, 549–572. [CrossRef]
56. Morello, J.P.; Bichet, D.G. Nephrogenic diabetes insipidus. Annu. Rev. Physiol. 2001, 63, 607–630. [CrossRef]
[PubMed]
57. Allan, F.N.; Rowntree, L.G. The Association of Diabetes Insipidus and Diabetes Mellitus. Endocrinology 1931,
15, 97–106. [CrossRef]
58. Chu, J.Y.; Lee, L.T.; Lai, C.H.; Vaudry, H.; Chan, Y.S.; Yung, W.H.; Chow, B.K. Secretin as a neurohypophysial
factor regulating body water homeostasis. Proc. Natl. Acad. Sci. USA 2009, 106, 15961–15966. [CrossRef]
[PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
